Analysts Anticipate Prelude Therapeutics Incorporated (NASDAQ:PRLD) to Post -$0.63 EPS

Analysts expect that Prelude Therapeutics Incorporated (NASDAQ:PRLDGet Rating) will report earnings of ($0.63) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Prelude Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.59) and the lowest estimate coming in at ($0.65). Prelude Therapeutics posted earnings of ($0.58) per share in the same quarter last year, which indicates a negative year over year growth rate of 8.6%. The firm is expected to announce its next earnings report on Monday, January 1st.

On average, analysts expect that Prelude Therapeutics will report full year earnings of ($2.60) per share for the current financial year, with EPS estimates ranging from ($2.64) to ($2.56). For the next year, analysts expect that the company will post earnings of ($2.56) per share, with EPS estimates ranging from ($2.68) to ($2.43). Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that follow Prelude Therapeutics.

Prelude Therapeutics (NASDAQ:PRLDGet Rating) last released its earnings results on Tuesday, May 10th. The company reported ($0.63) EPS for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.05.

A number of equities research analysts have recently commented on the company. Morgan Stanley cut their target price on Prelude Therapeutics from $20.00 to $19.00 and set an “overweight” rating on the stock in a research note on Thursday, March 17th. Barclays cut Prelude Therapeutics from an “overweight” rating to an “equal weight” rating and cut their target price for the stock from $20.00 to $12.00 in a research note on Monday, February 28th. Bank of America cut Prelude Therapeutics from a “buy” rating to a “neutral” rating and cut their target price for the stock from $50.00 to $10.00 in a research note on Tuesday, March 15th. Zacks Investment Research raised Prelude Therapeutics from a “hold” rating to a “buy” rating and set a $4.50 price target on the stock in a report on Saturday, May 14th. Finally, HC Wainwright lowered their price target on Prelude Therapeutics from $62.00 to $16.00 and set a “buy” rating on the stock in a report on Thursday, May 12th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, Prelude Therapeutics currently has an average rating of “Buy” and an average target price of $12.30.

Shares of NASDAQ PRLD traded up $0.12 during trading on Friday, reaching $4.75. The company had a trading volume of 157,361 shares, compared to its average volume of 270,289. Prelude Therapeutics has a 12-month low of $3.87 and a 12-month high of $43.55. The stock has a market cap of $226.56 million, a PE ratio of -1.84 and a beta of 1.71. The business’s 50-day moving average is $5.33 and its 200 day moving average is $8.92.

In other news, CFO Laurent Chardonnet bought 10,000 shares of the stock in a transaction on Wednesday, June 1st. The shares were bought at an average price of $4.23 per share, with a total value of $42,300.00. Following the completion of the acquisition, the chief financial officer now owns 24,500 shares in the company, valued at $103,635. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 77.38% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently bought and sold shares of PRLD. Wells Fargo & Company MN increased its position in Prelude Therapeutics by 7,230.2% in the fourth quarter. Wells Fargo & Company MN now owns 3,152 shares of the company’s stock worth $39,000 after buying an additional 3,109 shares in the last quarter. Point72 Hong Kong Ltd increased its position in Prelude Therapeutics by 141.7% in the fourth quarter. Point72 Hong Kong Ltd now owns 3,872 shares of the company’s stock worth $48,000 after buying an additional 2,270 shares in the last quarter. Legal & General Group Plc increased its position in Prelude Therapeutics by 32.3% in the fourth quarter. Legal & General Group Plc now owns 3,914 shares of the company’s stock worth $49,000 after buying an additional 956 shares in the last quarter. Rhumbline Advisers purchased a new stake in Prelude Therapeutics in the first quarter worth about $69,000. Finally, Ensign Peak Advisors Inc purchased a new stake in Prelude Therapeutics in the fourth quarter worth about $101,000. 73.80% of the stock is currently owned by institutional investors.

Prelude Therapeutics Company Profile (Get Rating)

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme.

Recommended Stories

Get a free copy of the Zacks research report on Prelude Therapeutics (PRLD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Prelude Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prelude Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.